{"entity":{"id":"beijing-xunsheng-biomedical","kind":"company","name":"Beijing Xunsheng Biomedical Research","aka":["Aeonvital","Xunsheng Biotech"],"tldr":"Beijing Xunsheng Biomedical Research grows a patient's own tumour-fighting immune cells, taken from the tumour itself, and gives them back in large numbers. Its first cell therapy, ReT01, is aimed at cervical cancer and is in an early trial in advanced solid tumours; it is also developing DNA vaccines against HPV.","summary":"Beijing Xunsheng Biomedical Research Co., Ltd. (Aeonvital), headquartered at the Zhongguancun (Daxing) cell and gene therapy park in Daxing, Beijing, was founded in March 2021, according to the company. It develops tumour-infiltrating lymphocyte (TIL) therapies using its TILAmp expansion platform and LentiVae lentiviral gene-modification platform, and nucleic-acid (DNA and mRNA) therapeutic vaccines using an engineered bacterial vector platform. The company describes ReT01 as China's first natural TIL product for cervical cancer, given without lymphodepletion and without IL-2 injection, and reports implied clinical trial approval from the National Medical Products Administration; a phase 1 study of ReT01 ACT in advanced solid tumours is registered (NCT06257680). AVL-101 is a DNA-based therapeutic HPV vaccine that started a phase 1 study in 2026, according to company news. Founded in 2021, according to the company. Its first registered cancer trial, NCT06257680, was posted on ClinicalTrials.gov in February 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"http://www.aeonvital.com/"},{"label":"ClinicalTrials.gov: phase 1 trial of ReT01 ACT in advanced solid tumours (NCT06257680)","url":"https://clinicaltrials.gov/study/NCT06257680"},{"label":"Company profile (Chinese)","url":"http://www.aeonvital.com/page141"}],"tags":[],"related":[],"cancers":["cervical"],"sections":["cell-therapy","immunotherapy"],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: aeonvital.com home, about, pipeline and TIL pages, in Chinese. The English company name is taken from the ClinicalTrials.gov sponsor field; the site gives only the Chinese name.","Efficacy claims on the company site (expansion rates, best-in-class statements) are the company's own and are not repeated. No financing was found on the pages read.","AVL-101 targets HPV infection and precancer as well as cancer; it is mentioned for completeness and not linked to a technology record."],"hq":"Beijing","country":"CN","companyType":"cell-therapy","website":"http://www.aeonvital.com/","founded":2021,"stage":"startup","investors":[],"funding":[]},"route":"/companies/beijing-xunsheng-biomedical/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}]}}